A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs APG 2449 (Primary)
Indications Brain metastases; Malignant-mesothelioma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Ascentage Pharma

26 Feb 2025 Planned End Date changed from 1 Feb 2025 to 1 Jan 2028.
26 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Dec 2027.
04 Jun 2024 Results(As of December 9, 2023, n=144 pts) safety and efficacy results of APG-2449 and demonstrating associations between this therapy and FAK signaling pathways , presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com